Prognostic indicators of relapse-free and overall survival in patients with high-risk primary breast cancer following high-dose chemotherapy.

被引：0
|
作者：
Somlo, G
Chu, P
Frankel, P
Chow, W
Forman, S
Leong, L
Margolin, K
Morgan, R
Shibata, S
Yen, Y
Doroshow, J
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[2] City Hope Comprehens Canc Ctr, Dept Biostat, Duarte, CA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
227
引用
收藏
页码：243 / 243
页数：1
相关论文
共 50 条
  • [31] Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer - A quality assessment study
    Svane, IM
    Homburg, KM
    Kamby, C
    Nielsen, DL
    Roer, O
    Sliffsgaard, D
    Johnsen, HE
    Hansen, SW
    ACTA ONCOLOGICA, 2002, 41 (7-8) : 675 - 683
  • [32] High-dose chemotherapy with autologous hematopoietic progenitor cell support for metastatic and high-risk primary breast cancer
    Bearman, SI
    Shpall, EJ
    Jones, RB
    Cagnoni, PJ
    Ross, M
    SEMINARS IN ONCOLOGY, 1996, 23 (01) : 60 - 67
  • [33] Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer
    GarciaCarbonero, R
    Hidalgo, M
    PazAres, L
    Calzas, J
    Gomez, H
    Guerra, JA
    Hitt, R
    Hornedo, J
    Colomer, R
    CortesFunes, H
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (10) : 3178 - 3184
  • [34] Five-year relapse-free survival and predictors of relapse following preoperative docetaxel and mitoxantrone for high-risk localized prostate cancer
    Rademacher, B. L.
    Garzotto, M.
    Higano, C. S.
    O'Brien, C. A.
    Janeba, N.
    Fazli, L.
    Lange, P. H.
    Lieberman, S.
    Beer, T. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] Should breast reconstruction be delayed in high-risk breast cancer patients (pts) receiving High-Dose Chemotherapy (HDC)?
    Petit, J
    Youssef, O
    Rjetjens, M
    D'Ambrosio, M
    Luini, A
    Massaron, S
    Vanazzi, A
    Martinelli, G
    BONE MARROW TRANSPLANTATION, 2001, 27 : S119 - S119
  • [36] Impact of her2/neu status on survival after high-dose chemotherapy in high-risk breast cancer patients.
    Kuzhan, O
    Ozet, A
    Arpaci, F
    Kurt, B
    Komurcu, S
    Ozturk, B
    Ataergin, S
    Gunhan, O
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 104S - 104S
  • [37] High-dose chemotherapy for patients with high-risk breast cancer - A clinical and economic assessment using a quality-adjusted survival analysis
    Marino, Patricia
    Roche, Henri
    Moatti, Jean-Paul
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (02): : 117 - 124
  • [38] Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
    V Drageset
    JM Nesland
    B Erikstein
    E Skovlund
    H Sommer
    G Anker
    E Wist
    S Lundgren
    J Bergh
    G Kvalheim
    Breast Cancer Research, 7
  • [39] Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy
    Drageset, V
    Nesland, JM
    Erikstein, B
    Skovlund, E
    Sommer, H
    Anker, G
    Wist, E
    Lundgren, S
    Bergh, J
    Kvalheim, G
    BREAST CANCER RESEARCH, 2005, 7 (Suppl 2) : S56 - S57
  • [40] Disease free survival as a predictor of overall survival in patients with high-risk endometrial cancer receiving adjuvant chemotherapy
    Kponee-Shovein, Kale
    Prabhu, Vimalanand S.
    Song, Yan
    Chen, Lei
    Cheng, Mu
    Li, Yeran
    Sun, Yezhou
    Hilts, Annalise
    Hua, Qi
    Lichfield, Jasmine
    Duska, Linda
    CLINICAL CANCER RESEARCH, 2024, 30 (05)
12345